Skip to main content

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.

Publication ,  Journal Article
Uschner, FE; Ranabhat, G; Choi, SS; Granzow, M; Klein, S; Schierwagen, R; Raskopf, E; Gautsch, S; van der Ven, PFM; Fürst, DO; Strassburg, CP ...
Published in: Sci Rep
September 28, 2015

Liver cirrhosis but also portal vein obstruction cause portal hypertension (PHT) and angiogenesis. This study investigated the differences of angiogenesis in cirrhotic and non-cirrhotic PHT with special emphasis on the canonical (Shh/Gli) and non-canonical (Shh/RhoA) hedgehog pathway. Cirrhotic (bile duct ligation/BDL; CCl4 intoxication) and non-cirrhotic (partial portal vein ligation/PPVL) rats received either atorvastatin (15 mg/kg; 7d) or control chow before sacrifice. Invasive hemodynamic measurement and Matrigel implantation assessed angiogenesis in vivo. Angiogenesis in vitro was analysed using migration and tube formation assay. In liver and vessel samples from animals and humans, transcript expression was analyzed using RT-PCR and protein expression using Western blot. Atorvastatin decreased portal pressure, shunt flow and angiogenesis in cirrhosis, whereas atorvastatin increased these parameters in PPVL rats. Non-canonical Hh was upregulated in experimental and human liver cirrhosis and was blunted by atorvastatin. Moreover, atorvastatin blocked the non-canonical Hh-pathway RhoA dependently in activated hepatic steallate cells (HSCs). Interestingly, hepatic and extrahepatic Hh-pathway was enhanced in PPVL rats, which resulted in increased angiogenesis. In summary, statins caused contrary effects in cirrhotic and non-cirrhotic portal hypertension. Atorvastatin inhibited the non-canonical Hh-pathway and angiogenesis in cirrhosis. In portal vein obstruction, statins enhanced the canonical Hh-pathway and aggravated PHT and angiogenesis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

September 28, 2015

Volume

5

Start / End Page

14573

Location

England

Related Subject Headings

  • rhoA GTP-Binding Protein
  • Signal Transduction
  • Rats
  • Neovascularization, Pathologic
  • Models, Biological
  • Liver Cirrhosis
  • Hypertension, Portal
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Hepatic Stellate Cells
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Uschner, F. E., Ranabhat, G., Choi, S. S., Granzow, M., Klein, S., Schierwagen, R., … Trebicka, J. (2015). Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep, 5, 14573. https://doi.org/10.1038/srep14573
Uschner, Frank E., Ganesh Ranabhat, Steve S. Choi, Michaela Granzow, Sabine Klein, Robert Schierwagen, Esther Raskopf, et al. “Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.Sci Rep 5 (September 28, 2015): 14573. https://doi.org/10.1038/srep14573.
Uschner FE, Ranabhat G, Choi SS, Granzow M, Klein S, Schierwagen R, Raskopf E, Gautsch S, van der Ven PFM, Fürst DO, Strassburg CP, Sauerbruch T, Diehl AM, Trebicka J. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015 Sep 28;5:14573.

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

September 28, 2015

Volume

5

Start / End Page

14573

Location

England

Related Subject Headings

  • rhoA GTP-Binding Protein
  • Signal Transduction
  • Rats
  • Neovascularization, Pathologic
  • Models, Biological
  • Liver Cirrhosis
  • Hypertension, Portal
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Hepatic Stellate Cells